Current role
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Mark C
The proxy statement of Acadia Pharmaceuticals Inc reports total compensation of $3,119,408 for Mark C in fiscal 2025, including a base salary of $546,428. Disclosed compensation is on record for 5 fiscal years.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Acadia Pharmaceuticals Inc (ACAD)
Proxy statement
Current
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Acadia Pharmaceuticals Inc
Other people whose current roles at this company are on record from its filings.
- Catherine Owen Adams CEO, Board Member
- Stephen R. Biggar Chairman, Board Member
- Mark C. Schneyer CFO
- Mark Schneyer CFO
- Brendan P. Teehan COO
- Austin D. Kim General Counsel
- James K. Kihara Chief Accounting Officer
- Adora Ndu Board Member
- Adora Ndu, Pharm.D., J.D. Board Member
- Daniel B. Soland Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Acadia Pharmaceuticals Inc (ACAD) | Schneyer | $546,428 | $3,119,408 |
| 2024 | Acadia Pharmaceuticals Inc (ACAD) | Schneyer | $518,470 | $2,517,513 |
| 2023 | Acadia Pharmaceuticals Inc (ACAD) | Schneyer | $484,842 | $2,591,204 |
| 2022 | Acadia Pharmaceuticals Inc (ACAD) | Schneyer | $467,283 | $2,353,204 |
| 2021 | Acadia Pharmaceuticals Inc (ACAD) | Schneyer | $398,183 | $3,182,819 |
Recent activity
No call appearances or filed executive changes recorded yet.